Adjuvant therapeutic effects of moxibustion on COVID-19: A protocol for systematic review and meta-analysis

Medicine (Baltimore). 2020 Nov 13;99(46):e23198. doi: 10.1097/MD.0000000000023198.

Abstract

Background: COVID-9 has become a global pandemic with severe health issues around the world. However, there is still no effective drug to treat the disease, and many studies have shown that moxibustion plays a positive role in adjuvant treatment of COVID-19. Therefore, this meta-analysis is designed to evaluate the efficacy of moxibustion for COVID-19.

Methods: The relevant randomized controlled trials will be systematically retrieved from the electronic database, including PubMed, Embase, Cochrane Clinical Trials Database, Web of Science, and China National Knowledge Infrastructure, without restrictions on publication status and language. Two reviewers will independently review all included studies and assess the risk of bias. Two reviewers will independently extract data from the included studies based on a pre-designed standardized form. Any disagreements will be resolved by consensus. The meta-analysis will be performed with RevMan (V5.3.5) software.

Result: The results of this study will be published in a peer-reviewed journal.

Conclusion: This ongoing meta-analysis will provide up-to-date evidence of the efficacy of moxibustion for patients with COVID-19.

Registration: The meta-analysis has been prospectively registered in PROSPERO (CRD42020211910).

MeSH terms

  • Betacoronavirus
  • COVID-19
  • Coronavirus Infections / therapy*
  • Humans
  • Meta-Analysis as Topic
  • Moxibustion / adverse effects
  • Moxibustion / methods*
  • Pandemics
  • Pneumonia, Viral / therapy*
  • Randomized Controlled Trials as Topic
  • Research Design
  • SARS-CoV-2
  • Systematic Review as Topic